Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours Β· Estimated delivery Aug 15 - Aug 20
Participants received weekly subcutaneous injections of retatrutide at 0.5 mg, 4.0 mg, 8.0 mg, or 12 mg, placebo, or 1.5 mg dulaglutide over 36 weeks
Patients often find that smaller, more satisfying meals become easier to maintain once appetite decreases
CJC-1295 is not approved by the FDA or any regulatory agency for therapeutic or cosmetic use
Side effects are most common at the start of treatment or after increasing the dose , as the body adapts to the medication
This does not mean treatment has failed
US$ 22.78
US$ 25.18
US$ 29.00
US$ 22.61
